Essai clinique NCT04198766 · Non-Small Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Essai clinique NCT04198766 (phase I/II) est «en recrutement» sur ClinicalTrials.gov.

Pathologie: Non-Small Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer · Interventions enregistrées: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) · Dates enregistrées (source): 2019-12-10, 2033-07, 2019-12-13, 2026-11-06.

Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Source: https://clinicaltrials.gov/study/NCT04198766